Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure

Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure

Abstract Objective Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outcomes via beneficial effects on systemic and cardiac inflammation and car...

Full description

Bibliographic Details
Main Authors: Dennis D. Wang, Anna V. Naumova, Daniel Isquith, Jamie Sapp, Kim A. Huynh, Isabella Tucker, Niranjan Balu, Anna Voronyuk, Baocheng Chu, Karen Ordovas, Charles Maynard, Rong Tian, Xue-Qiao Zhao, Francis Kim
Format: Article
Language:English
Published: BMC 2024-06-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Inflammation
IL-1B
PBMC respiration
CMRI
Cardiac fibrosis
Online Access:https://doi.org/10.1186/s12933-024-02294-z

Internet

https://doi.org/10.1186/s12933-024-02294-z

Similar Items